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Intercellular adhesion molecule-l (I CAM -1), a cell-adhesion 
molecule critically involved in leukocyte trafficking and ad-
herence, displays tissue-specific and cytokine-specific ex-
pression profiles. Although human dermal microvascular en-
dothelial cells (HDMEC) constitutively express ICAM-l, 
keratinocytes (HK) do not. Interleukin-l (IL-l) upregulates 
ICAM-l expression in HDMEC, but fails to do so in either 
HK or A43l, a human squamous carcinoma cell line, even 
though both have IL-l receptors and express ICAM-l on 
exposure to o~her cytokines. We have previously character-
ized a human ICAM-l genomic clone that contains the 5' 
flanking transcriptional regulatory region. To test the hy-
pothesis that tissue- and cytokine-specific ICAM-l gene ex-
pression results from the interaction of constitutive and in-
ducible tissue-specific trans-acting factors with distinct 
cis-eleITlents of the ICAM-l gene, various ICAM-l- based 
reporter gene (CAT) plasmids were constructed. Transcrip-
tional activity of these various constructs was assessed after 
transient transfection into HDMEC and A431. A critical 
L eukocyte cell-adhesion molecules (CAMs) are cell sur-. face proteins that allow specific homotypic as well as heterotypic interactions between leukocytes and other cells. Differential constitutive and induced expression profiles of certain cell-adhesion molecules are critical 
events in the migration and cellular interactions that are intrinsic to 
such diverse processes as cutaneous inflammation, wound repair, 
and tumor invasion. Intercellular adhesion molecule-l (ICAM-l) is 
a cell-adhesion molecule that is constitutively expressed on the sur-
face of numerous cell types, including large- and small-vessel endo-
thelial cells [1-4], and is inducible on other cells, such as human 
keratinocytes (HK) [5]. ICAM-1 is the specific ligand for lympho-
cyte function-associated antigen-1 (LFA-l), a cell-surface protein 
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1 CAM -1 region was identified that conferred enhanced ex-
pression of CAT in HDMEC and suppressed expression of 
CAT in A431. This same region further enhanced CAT 
expression in transfected HDMEC treated with IL-la, yet no 
such enhancement was seen with IL-l treatment of identi-
cally transfected A431. However, treatment of A43l trans-
fectants with IFNy did result in enhanced CAT expression, 
demonstrating reversal of A43l cell context suppression of 
the ICAM-l-based reporter gene construct. These data im-
plicate the existence of both tissue- and cytokine-specific 
responsive elements in the 5' flanking region of the ICAM-l 
gene and demonstrate that regulatory effects directed by such 
elements are dependent upon their cellular context. More-
over, they provide the basis for identification of specific cis-
acting genetic elements, the trarls-acting factors with which 
they interact, and the molecular mechanisms by which they 
regulate transcription of the ICAM-l gene.] Invest Dermatol 
100:753-758, 1993 
expressed on all leukocytes, as well as Mac-l, which is expressed on 
neutrophils and monocytes [6 - 13]; both LFA-1 and Mac-1 are 
members of the integrin fJ2 subfamily of adhesion molecules. The 
coordinated expression and/or induction of CAMs SlIch as ICAM-1 
allows leukocytes to bind to endothelial cells at sites of inflamma-
tion. Other CAMs that are also involved in the initialleukocyte-en-
dothelial cell interaction include P-selectin (also known as GMP-
140) [14,15], E-selectin (also known as ELAM-1) [16,17], and 
vascular cell adhesion molecule-1 (VCAM-1) [18,19]. The regu-
lated induction of these CAMs, which are not constitutively ex-
pressed on the endothelial cell-surface, in concert with upregulated 
expression of ICAM-1, allows not only initial leukocyte binding, 
but also transmigration into the tissue, and subsequent interaction 
with specific target cells, such as HK. 
In addition, specific cytokines are capable of differentially regulat-
ing ICAM-1 expression on endothelial cells, HK, and other cells. 
Treatment of human dermal microvascular endothelial cells 
(HDMEC) ill vitro with interferon y (IFNy), tumor necrosis factor 
(TNFa), or interleukin 1 (IL-l) results in increased ICAM-1 cell 
surface and mRNA expression [20]. Induction ofICAM-l on HK, 
which do not constitutively express this CAM, o.ccurs afte~ treat-
ment with either IFNy or TNFa [21], but not WIth IL-1 stlmula-
tion. Therefore, two cell types, HK and HD~C, demonstrate 
tissue-specific and cytokine-specific differences WIth respect to con-
stitutive and induced ICAM-l expression. HK and HDMEC are 
known to be active participants, as well as targets, in cutaneous 
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inflammatory and immunologic processes. Thus, the delineation of 
precise molecular mechanisms that regulate tissue-specific and cy-
tokine-specific expression ofICAM-l in these cells is important to 
our understanding of the cutaneous immunologic and inflamma-
tory response. Our laboratory has recently isolated and character-
ized a human genomic clone that contains the 5' regulatory region 
of the ICAM-l gene [22]. Utilizing specific portions of this ge-
nomic clone, we have examined ill vitro the transcriptional regula-
tion of the ICAM-l gene with regard to tissue-specific and cyto-
kine-specific signals in HDMECs and A431, a human squamous cell 
carcinoma cell line, and herein present data that correlate the differ-
ential expression profiles seen ill vivo with distinct regulatory re-
gions of this gene. 
MATERIALS AND METHODS 
Cell Culture HDMEC were isolated as previously described 
from neonatal foreskins, utilizing trypsinization and Percoll gra-
dient centrifugation [23]. Characterization and analysis for £urity 
was performed through staining for von Willebrand factor (factor 
VIII -associated antigen) and uptake of acetylated LDL. The cells 
were maintained through s~quential passages, and typically utilized 
in passages 3,- 6. Cells were grown in Endothelial Cell Basal Media 
(Clonetics Corp., San Diego, CA), supplemented with 30% nor-
mal human serum (Irvine, Santa Anna, CA), 2 mM L-glutamine 
(Irvine), 5 X 10-4 M cAMP (Sigma Chemical, St. Louis, MO), 
1 Ilg/ml hydrocortisone acetate (Sigma), 5 ng/ml epidermal 
growth factor (Clonetics), and an antibiotic cocktail of 100 U Iml 
streptomycin, 100 U/ml penicillin, 251lg/ml amphotericin B (Ir-
vine), and 10 Ilg/ml ciprofloxin (Miles Pharmaceuticals, West 
Haven, CT). Human umbilical vein endothelial cells (HUVEC) 
were isolated from umbilical veins treated with collagenase as previ-
ously described [24]. The cells were sequentially passaged and typi-
cally utilized in passages 3-8. Cells were cultured and maintained 
in Medium 199 (GIBCO, Grand Island, NY) supplemented with 
20% fetal bovine serum, 100 Ilg1 ml endothelial cell growth supple-
ment (Biomedical Te.chnologies, Stoughton, MA), 50 Ilg/ml hepa-
rin, 2 mM L-glutamme, and 100 U/ml streptomycin, 100 U/ml 
penicillin, 250 Ilg/ml amphotericin B. A431 were obtained from 
American Type Culture Collection (Rockville, MD) and were cul-
tured in Dulbecco's modified Eagle's medium (4.5 gil glucose) 
(GIBCO) supplemented with 3 mM L-glutamine, 10% heat-inac-
tivated fetal bovine serum, 100 U I ml penicillin, 250 Ilg1 ml am-
photericin B, and 100 Ilg/ml streptomycin. 
Reagents and Cytokines Specific reagents and their sources in-
cluded recombinant human IFNy (Amgen Biologicals, Thousand 
Oaks, CA) and human IL-la (Biologic Response Modifiers Branch, 
NCI, NIH, Frederick, MD). Dosage and treatment intervals were 
determined by previous experiments with the cytokine-responsive-
ness of A431 and HDMEC ill vitro. 
Transfections and Assays of Activity of ICAM-l-Based 
Chloramphenicol-Acetyl Transferase (CAT) Reporter Gene 
Constructs Isolation and characterization of the 5' portion of the 
human ICAM-l gene by our laboratory has been previously de-
scribed [22]. The exon/intron organizational structure of this 17.3-
kb genomic clone, the 2.05-kb subfragment that contains the imme-
diate 5' flanking region, and the ICAM-l - based CAT reporter 
gene constructs utilized in these studies are schematically shown in 
Fig 1. The 2.05-kb subfragment contains the transcription initia-
tion site, first exon, a portion of the first intron, and 1350 bp of 5' 
flanking region. Restriction endonuclease sites were utilized to 
create several specific fragments, which were introduced into CAT 
reporter gene constructs [22]. The 282-bp Hil1dIIl/SstI fragment, 
designated HS, extending 277 bp 5' of the transcription start site, 
was subcloned into a promoterless CAT expression vector, pCAT-
Basic (Promega, Madison, WI), resulting in construct pHS-CAT. 
pBS-CAT was constructed with the 1165 Bg III I SstI (BS) fragment 
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of the genomic ICAM-1 subclone and contains the region of the HS 
fragment, as well as an additional upstream 883 bp of the 5' flank-
ing region. pBH-CAT contains the 883 upstream BglII/HilldIlI 
(BH) fragment, but does not include the immediate 5'f1anking re-
gion contained in the HS fragment. pCAT-Control (pCAT-C, 
Promega), which contains the SV 40 promoter and enhancer, served 
as a positive control for CAT expression, and pCAT -Basic (pCAT-
B, Promega), which contains no promoter or enhancer, served as a 
negative control for CAT expression. Subconfluent A431 cell cul-
tures (106 cells/75 cm2 tissue culture dish) were transfected by the 
calcium phosphate precipitation technique [25] with 10 Ilg plasmid 
DNA utilizing techniques and procedures as previously described 
[22]. Subconfluent HDMEC cultures (5 - 7.5 X 105 cells/75 cm2 
tissue culture dish) were also transfected by this technique; how-
ever, these cells proved to be more sensitive to this procedure. There-
fore, varying treatment regimens were employed in an attempt to 
minimize cell insult and optimize DNA transfection and expres-
sion. We established that transfection of earlier-passage HDMEC, 
plated at near-confluence, with a 6-8-h exposure to the plasmid 
DNA/calcium phosphate precipitant, resulted in better cell viabil-
ity and higher reporter gene expression. Sixteen to twenty-four 
hours after transfection and replenishment with appropriate media, 
transfectants were exposed to selected cytokines for 18-24 h prior 
to preparing cellular lysates for CAT analysis. Lysates were prepared 
as previously described [22]. IFNy was utilized at 250 U/ml; IL-la 
was utilized at 80 U Iml. Protein concentration of celllysates were 
determined spectrophotometrically [25], and Iysates were normal-
ized for protein concentration prior to assay. Previous studies had 
established that the constructs utilized displayed near identical 
transfection efficiencies within any given cell type. Cell Iysates 
were assayed for CAT enzyme expression as previously described 
[22] using HC-Iabeled chloramphenicol (Amersham Corp., Arling-
ton Heights, IL) as substrate. Chloramphenicol and acetylated deriv-
atives were resolved by thin-layer chromatography, and percent 
conversions of substrate to acetylated forms were determined via 
scintillation counting of appropriate areas of the chromatograph 
after autoradiography was performed. 
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Figure 1. Schematics of the organizational structure of the human ICAM-1 
genomic clone ),6 [22]. expanded 2.05-kb subfragment cO!ltaining immedi-
ate 5' flanking region, and ICAM-1-based CAT reporter gene constructs. 
In the upper genomic clone schematic, the 5' flanking and intronal regions 
are indicated by the llJiIl Ilorizolilal black lill e, and individual exons are indi-
cated by the differentially shaded vertical bars. The 2.05-kb BcoRl suhfrag-
ment, which contains the first exon, a portion of the first intron, transcrip-
tion initiation site, and 1350 bp of 5' flanking region, is indicated by the 
thick horizolltal bar, and the organizational structure of this subregion is 
shown below it in expanded form. The belli arrow marks the previously 
identified transcription initiation site [22), and the relative locations of re-
striction endonuclease sites utilized to isolate specific fragments are indi-
cated: B, BglII; H, HitldIII; and S, Ssl!. Specific fragments HS, BH, and BS 
were then cloned into CAT expression vectors, resulting in the ICAM-1 -
based CAT constructs pHS-CAT, pBH-CAT, and pBS-CAT, depicted sche-
matically at the bottom. 
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Figure 2. Differential tissue-specific regulation of transcription via a por-
tion of the 5' flanking region of the human ICAM-l gene. Representative 
experim.ent illustrating relative transcriptional activity of specific ICAM-l-
based CAT plasmids transiently transfected into A431 cells and HDMEC. 
Top, autoradiography of thin-layer chromatography of CAT reporter assays. 
(CM, 1 4 C-labeled chloramphenicol substrate; l-Ac-CM and 3-Ac-CM, 
mono-acetylated products). Middle, graphic form of the relative CAT en-
zyme activity in each transfectant as percent conversion of 14C-labeled 
chloram.phenicol to acetylated product. Bottom, schematic illustration of the 
ICAM-1 - based CAT reporter gene constructs utilized. 
RESULTS 
The 5' Flanking Region of the ICAM-1 Gene Contains a 
Functional, Potent Promoter when Transiently Transfected 
into HDMEC As previously reported, the 282-nucleotide 
HindIII/SstI fragment (HS) can function as a potent promoter of 
CAT expression in A431 cells [22]. In HDMEC as well, the inserted 
HS fragment functioned as a potent promoter when pHS-CAT was 
transiently transfected into these cells. Representative experiments 
in A431 and HDMEC are shown illustrating the autoradiography 
of CAT assays and calculated percent CAT conversion (Fig 2) . 
Neither the negative control pCAT-B (not shown), nor the con-
struct driven by the 883-bp ICAM-1 upstream fragment (BH) , re-
sulted in CAT expression in either cell type, demonstrating that this 
upstream region does not contain a functional promoter that is 
biologically operative within the cellular context of either A431 or 
HDMEC. 
The 5' Flanking Region of the ICAM·1 Gene Demonstrates 
Differential Tissue-Specific Responsiveness when Tran-
siently Transfected into A431 and HDMEC In multiple anal-
yses, pHS-CAT resulted in CAT expression in both A431 and 
HDMEC (Fig 2). However, the construct containing 1165-bp BS 
fragment (pBS-CAT) , which includes the basal promoter region 
contained in HS as well as the contiguous 883-bp upstream region, 
resulted in differential CAT expression when transfected into A431 
and HDMEC (Fig 2). In A431, conversion of14C chloramphenicol 
to acetylated product following transfection with pBS-CAT was 
routinely lower than CAT expression seen with pHS-CAT, indi-
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cating the presence of a functional repressor element within the 
upstream region that was active within the A431 cellular context. 
Conversely , in HDMEC, pBS-CAT expression was routinely as 
great or greater than that seen with pHS-CAT, thus demonstrating 
no evidence within this endothelial cell context of an active up-
stream repressor. The possibility that the putative upstream repres-
sor element, which was active when pBS-CAT was transfected into 
A431, was derepressed within HDMEC because of significant dif-
ferences in culture conditions was investigated. A431 cells were 
cultured in HDMEC media and transfections were performed with 
pBH-CAT, pHS-CAT, and pBS-CAT. The repressor activity of the 
ICAM-1 5' flanking region of the BS fragment in A431 remained 
active in A431 cells cultured in HDMEC media as well (data not 
shown). Therefore, in A431, a human keratinocyte-like cell line, 
transfection of pBS-CAT resulted in decreased reporter gene ex-
pression as compared to pHS-CAT. In HDMEC, however, pBS-
CAT demonstrated equivalent or increased expression of acetylated 
product. These results are analogous to ill villo ICAM-1 expression 
within these two different tissue contexts. The pBS-CAT construct 
contains a greater amount of the ICAM-l transcriptional regulatory 
region and its expression in HDMEC versus A431 is quite similar to 
the expression profiles of ICAM-1 as seen in endothelial cells and 
keratinocytes itl lIivo. That is, there is constitutive expression of 
ICAM-l in endothelial cells, and little to no expression in keratino-
cytes. 
Enhancer Activity of the 5' Flanking Region of the ICAM-1 
Gene Demonstrates Differential Cytokine Responsiveness 
that Is Cellular-Context Dependent Cytokine-specific respon-
siveness of the ICAM-l gene was studied through transfection of 
ICAM-1-hased reporter gene constructs into A431 or HDMEC 
followed by cytokine stimulation of the transfected cells. Parallel 
transfections with pBH-CAT or pCAT-B, pHS-CAT, and pBS-
CAT were followed by cytokine stimulation with IL-1a (80 UI 
ml), or IFNy (250 U/ml) for 16-24 h prior to lysate preparation 
and CAT assays . Previous studies in our laboratories had established 
that these dosages and times of exposure were optimal for induction 
of expression of the endogenous ICAM-1 gene in both A431 and 
HDMEC. A431 transfected with pBS-CAT did not demonstrate 
increased CAT expression when treated with IL-1, as shown by 
continued low conversion rates of chloramphenicol to acetylated 
product (Fig 3). However, A431 transfected with pBS-CAT did 
demonstrate enhanced responsiveness when treated with IFNy (Fig 
3), indicating that upstream enhancers of the ICAM-1 gene are 
functional within A431 cells when transfectants are exposed to 
signals appropriate for these cells. The expression following IFNy 
was driven to a level greater than that seen with untreated pBS-
CAT transfectants, and, in fact, greater than was seen with the 
potent pHS-CAT construct. Thus, similar to the failure of the en-
dogenous ICAM-1 gene within keratinocytes and A431 cells to 
respond to IL-1 stimulation of these cells, ICAM-1-based reporter 
gene constructs did not display enhanced expression in response to 
IL-1 stimulation when transfected into a keratinocyte-like cellular 
context. 
In contrast to keratinocytes and A431, HDMEC consti~tively 
express higher levels of ICAM-l and have been shown to l~crease 
ICAM-1 expression after IL-l stimulation. Similarly, IL-l stimula-
tion ofHDMEC transfected with pBS-CAT, in contr~st to :'-431 
cells, lead to markedly increased reporter gene expressIOn (Fig 4). 
No enhancement of CAT expression was evident following IL-1 
treatment of cells transfected with the pHS-CAT construct. Fo~r 
similarly performed experiments in HDMEC are shown graphi-
cally in Fig 5, and demonstrate that IL-1-indllced enhancement of 
CAT expression is seen only with the larger pBS-CA~ const.ru~t, 
indicating that an IL-1 responsive element is not contall1ed wl~I~1Il 
the small er HS fragment. Experiments were also performed Utlltz-
ing large-vessel endothelial cells (HUVEC), which in vitro constitu-
tively express ICAM-1 and upreglliate ICAM-l in response to IL-1, 
as well. IL-1 - induced enhanced CAT expression was observed 
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Figure 3_ Cytokine responsiveness of ICAM-l-based CAT constructs 
transiently transfected into A431 cells. Representative experiment illustrat-
ing relative transcriptional activity of specific ICAM-l- based CAT plas-
mids transiently transfected into A431 cells and subsequently treated with 
the indicated cytokines. Transfectants were exposed to IL-la at a fina l 
concentration of80 U/ml for 16 h, orto IFNyat250 U/ml for 16 h, priorto 
lysate preparation. pHS-CAT did not show enhanced expression in response 
to IL-l, nor did negative (pCAT-Basic) or positive (pCAT-Control) pi as-
mids show enhanced expression with either cytokine (data not shown). The 
panels depict autoradiographic data, quantitation of percent CAT conver-
sion, and constructs utilized as described in Fig 2. 
with the transfected pBS-CAT construct, but not with pHS-CAT, 
in these cells as well (data not shown) . 
DISCUSSION 
In these studies, we have uti lized the 5' flanking region of the 
human ICAM-I gene to investigate the tissue-specific and cyto-
kine-specific regulation of the ICAM-I gene within the cellular 
context of A43I and HDMEC. Using ICAM-I-based reporter 
gene constructs, we have identified a portion of the 5' regulatory 
region of the human ICAM-1 gene, located upstream to the basal 
promoter, that confers differential gene expression in two cell types. 
Transfections with constructs containing this region confer re-
pressed expression in A431, as previously reported [22]. and en-
hanced expression of the gene in HDMEC, as presently shown. 
Interestingly, when using the pBS-CAT construct, which as the 
largest, more inclusive construct utilized more closely approximates 
the wild type biologic situation, expression and responsiveness of 
the reporter gene product was analogous to expression of the endog-
enous ICAM-I gene within each in vivo cellular context. That is, 
expression profiles of the reporter gene product reflected the ex-
pression of ICAM-1 in each cell type. A431 constitutively express 
ICAM-1 at very low levels, and transfection with the pBS-CAT 
construct resulted in decreased gene expression, demonstrating 
constitutive repressor activity within this cellular context. In con-
trast, transfection of pBS-CAT into HDMEC demonstrated in-
creased expression of the reporter gene product, and these cells 
constitutively express ICAM-1 at higher levels in vitro and in vivo. 
The shorter pHS-CAT construct was expressed well in both cellular 
contexts, demonstrating the biologic functionality and potency of 
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Figure 4_ Cytokine responsiveness of ICAM-l- based CAT constructs 
transiently transfected into HDMEC. Representative experiment illustrat-
ing relative transcriptional activity of specific ICAM-l - based CAT plas-
mids transiently transfected into HDMEC and subsequently treated with 
IL-l. Transfectants were exposed to IL-1a at a final concentration of 80 
U/ml for 16 h prior to lysate preparation. There was no enhancement of 
positive control plasmid (pCAT -Control) expression following IL-1a stim-
ulation (data not shown). The panels depict autoradiographic data, quantita-
tion of percent CAT conversion, and constructs utilized as described in Fig 2. 
the basal promoter contained within the HS fragment. Studies uti-
lizing the pHS-CAT construct also indicate that the regulatory 
regions and cis-elements required for both tissue-specific repression, 
as seen with transfections into A431 cells, and IL-1 enhancement, as 
seen with transfections into HDMEC, are not contained within the 
HS fragment but reside within the larger 883-bp upstream BH 
fragment. 
Using investigative approaches similar to those utilized in these 
studies, the tissue-specific regulation of the rat insulin gene in pan-
creatic and non-pancreatic cells has been studied by Nir et al [26] . 
These researchers hypothesized that tissue-specific regulation of 
insulin gene expression was dependent upon the differential expres-
sion and activity of both negative and dominant trans-acting factors 
that either repressed or promoted insulin gene expression, depend-
ing upon cellular context. These researchers demonstrated that the 
activity of a rat insulin gene enhancer was acted upon by a negative 
trans-acting factor present in non-insulin expressing cells, and that 
the activity of such a repressor factor was suppressed by a dominant 
trans-acting factor present in insulin-producing cells. Likewise, 
Junker et al [27] have studied immunoglobulin production in B-
cell/fibroblast hybrids and have described the absence in fibroblasts 
of a B-cell- specific transcription factor that is necessary for immu-
noglobulin gene expression. Our current work, buttressed by find-
ings such as these, illustrates that the differential expression of the 
ICAM-1 gene is dependent upon the molecular interaction of spe-
cific regions of the ICAM-1 gene, which is identical within all cells, 
with factors that are differentially expressed and induced within 
different cellular contexts. 
Utilizing the 5' regulatory region of the ICAM-I gene, our labo-
ratory has demonstrated that a specific region of this gene, con-
tained within the I165-bp BS fragment, contains not only the basal 
promoter region, but also a functional IL-I responsive region that 
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Figure 5. Composite data of IL-l responsiveness of ICAM-l- based con-
suucts transiently transfected into HDMEC. The bar graph depicts compos-
ite CAT expression data of multiple separate transfection experiments in 
which negative control (pCATB). pHS-CAT (HS), and pBS-CAT (BS) 
HDMEC transfectants were treated with IL-1a at 80 U/ml for 16 h prior to 
lysate preparation and CAT assay. T he relative conversion of 14C-labeled 
chloramphenicol to acetylated product is depicted along the Y axis (± SEM), 
with conversion rates normalized to a percent conversion value for untreated 
pBS-CAT expression arbitrarily set at a value of 1 (n = 4 for treated and 
untreated pCAT-Basic, pBS-CAT, and untreated pHS-CAT; n = 3 for IL-
l- treated pHS-CAT). rCAM-l-based and control CAT reporter gene con-
structs utilized are indicated along the x axis. 
can be activated within the cellular context of endothelial cells, but 
cannot be activated within the context of keratinocyte-like cell 
lines, such as A431. A431 cells have been found to have similar 
induction profiles as HK for expression of ICAM-l [28] ; IL-l 
stimulation does not induce ICAM-1 expression in either cell type. 
However, HK and A431 are known to express IL-l receptors (II-lr) 
[29] . It has recently been demonstrated that HK constitutively pro-
duce IL-l receptor antagonist (IL-l raj [30] that is capable of inter-
acting with the IL-1 receptor. Occupancy of the IL-1r with IL-1ra 
does not result in cell activation, but rather acts as a competitive 
inhibitor of IL-l stimulation [31] . Within the context of our stud-
ies, occupation of A431 or HK IL-lr by IL-1ra may, in fact, preclude 
sufficient IL-1 activation of these cells and the subsequent induction 
of secondary signals that are required for enhancement of ICAM-1 
gene expression within this cellular context. 
Although such a mechanism with regard to ICAM-1 expression 
~ at present speculative, the differential cytokine responsiveness 
demonstrated in these experiments is again analogous to the in vivo 
cellular situation. The cytokine responsiveness of many genes has 
been linked to the activation and/or induction of numerous second 
messengers [32], trans-acting factors [33,34]' and protooncogenes 
[35] . In human fibroblasts, IL-l and TNFa induction of the IL-6 
gene has been mapped to a 5' portion of this gene; the cis-element in 
this gene that was both necessary and sufficient for IL-1- induced 
enhancement was found to contain a sequence homologous to an 
NFKB-like element [33]. In addition, Osborn et al [36] characterized 
TNFa and IL-1 induction of the human immunodeficiency virus 
enhancer by activation of the trans-acting factor NFKB. Finally, 
Colotto et al [35] have characterized the induction of another trallS-
acting factor, c-fos, in HUVEC following IL-1 stimulation. This 
&ctor, in concert with another oncogene product, c-jun, forms a 
potent, heterodimeric trallsactivating protein that binds to the con-
sensus cis-element sequence designated AP-1. Both consensus AP-1 
and NFKE binding sites are located within the 883-bp upstream 
region (EH) of the ICAM-1 gene, and these studies have demon-
Itrated that this region is required for the functional regulation of 
ICAM-l expression in response to specific signals. Thus, there are 
several candidate trails-acting factors and consensus cis-elements 
that may be involved in both tissue-specific repression and IL-1-
induced enhancement of ICAM-l gene expression. 
In conclusion, these findings provide the basis for identification 
of specific cis-acting genetic elements within the 5' flanking region 
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of the human ICAM-1 gene that dictate the level of gene transcrip-
tion in response to both cellular context and IL-1 stimulation. Char-
acterization of tissue-specific and cytokine-specific elements within 
the ICAM-1 gene will allow identification of the tram-acting fac-
tors mediating these regulatory events. Deletional analysis is 
currently underway to determine whether previously characterized 
or other as yet undefined elements and factors are critical to either 
the tissue-specific or cytokine-specific regulatory responses of the 
ICAM-1 gene that we have observed. 
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